DEXTROSTAT Drug Patent Profile

Which patents cover Dextrostat, and what generic alternatives are available?

Dextrostat is a drug marketed by Shire and is included in one NDA.

The generic ingredient in DEXTROSTAT is dextroamphetamine sulfate. There is one drug master file entry for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the dextroamphetamine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dextrostat

A generic version of DEXTROSTAT was approved as dextroamphetamine sulfate by BARR on January 31^st, 2001.

Summary for DEXTROSTAT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	17
DailyMed Link:	DEXTROSTAT at DailyMed

US Patents and Regulatory Information for DEXTROSTAT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shire	DEXTROSTAT	dextroamphetamine sulfate	TABLET;ORAL	084051-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Shire	DEXTROSTAT	dextroamphetamine sulfate	TABLET;ORAL	084051-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Dextrostat Market Dynamics and Financial Trajectory

Last updated: August 4, 2026

Dextrostat is the former brand name for immediate-release dextroamphetamine sulfate tablets, an FDA-approved Schedule II central nervous system stimulant. Its commercial value has shifted from branded-product economics to a low-margin generic market. Public filings do not disclose standalone Dextrostat revenue, and the brand does not have a visible active-patent or regulatory-exclusivity position that would support premium pricing. Current market exposure is tied to generic dextroamphetamine supply, controlled-substance quotas, manufacturing capacity, and persistent ADHD treatment demand. [1][2]

What is Dextrostat and what is its FDA status?

Dextrostat contains dextroamphetamine sulfate, the dextrorotatory amphetamine salt. The immediate-release tablet was approved for narcolepsy and attention-deficit/hyperactivity disorder, subject to the labeling and abuse, misuse, and dependence warnings applicable to amphetamine stimulants. [1]

Attribute	Dextrostat
Active ingredient	Dextroamphetamine sulfate
Dosage form	Immediate-release tablet
Common strengths	5 mg, 10 mg, and 15 mg historically associated with the product
Therapeutic categories	ADHD and narcolepsy
FDA pathway	NDA approval for the branded product
Controlled-substance classification	Schedule II
Primary competitors	Generic dextroamphetamine sulfate tablets, Dexedrine tablets, extended-release amphetamine products, methylphenidate products
Current commercial position	Mature or discontinued brand with generic substitution
Public standalone revenue	Not disclosed

The FDA Drugs@FDA record identifies Dextrostat as an older product rather than a recent product launch. FDA records distinguish between a product being discontinued for commercial reasons and a product being withdrawn for safety or efficacy concerns. That distinction matters: a discontinued branded listing does not by itself indicate a safety withdrawal. [1]

When did Dextrostat lose market exclusivity?

Dextrostat lost meaningful market exclusivity decades ago. The product’s commercial position is consistent with an old small-molecule immediate-release stimulant that has been exposed to generic competition for many years.

The principal exclusivity milestones are:

Exclusivity issue	Dextrostat position
New chemical entity exclusivity	Expired long ago
Five-year Hatch-Waxman exclusivity	Not commercially relevant today
Three-year clinical-investigation exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current economic effect
Active brand patent moat	No visible current moat supporting branded pricing
Generic substitution	Established

For a product approved in the late 1970s or early 1980s, any statutory regulatory exclusivity has expired. The relevant commercial question is no longer when exclusivity ends. It is whether suppliers can consistently manufacture and distribute dextroamphetamine sulfate tablets within the controlled-substance quota system.

What patents protect Dextrostat?

No material active patent estate is apparent for the original Dextrostat immediate-release tablet.

The product uses an established active pharmaceutical ingredient and a conventional oral tablet. The core composition, therapeutic use, and immediate-release presentation are long-standing technologies. Any historical patent protection associated with the brand would have expired before the current generic market developed.

The likely IP profile is:

IP category	Commercial assessment
Active ingredient patent	Expired
Basic tablet formulation patent	Expired or commercially irrelevant
Method-of-use patent for ADHD	No meaningful current protection for the original brand
Manufacturing patent	No identified patent barrier specific to ordinary dextroamphetamine tablets
Trademark	Historically useful for brand recognition, but insufficient to prevent generic substitution
Trade secrets	Potentially relevant to manufacturing quality and supply reliability, not market exclusivity

The absence of a meaningful patent barrier does not eliminate operational barriers. Dextroamphetamine is a controlled substance. Manufacturers must obtain DEA registration, comply with quota allocations, maintain diversion controls, and meet FDA current good manufacturing practice requirements. Those obligations can restrict the number of reliable suppliers even when the product is legally generic. [3][4]

What is the Orange Book status of Dextrostat?

The Orange Book is relevant to determining listed patents and therapeutic-equivalence status for approved prescription drug products. Dextrostat’s commercial significance is limited because an old immediate-release stimulant does not appear to have an active Orange Book patent listing that protects a differentiated formulation or blocks generic entry.

The relevant Orange Book conclusions are:

1. The original product is an old NDA product.
2. Any historical patent listings do not provide a current commercial exclusivity window.
3. Generic dextroamphetamine sulfate tablets can compete through abbreviated new drug applications.
4. Orange Book listing status should be checked by strength and applicant because product records and marketing status can change over time. [2]

The brand’s practical protection comes from prescribing familiarity, pharmacy availability, and patient continuity rather than patent rights.

How large is the Dextrostat market?

There is no reliable public market-size figure for Dextrostat as a standalone brand. Its revenue cannot be reconstructed from public company filings because manufacturers generally report dextroamphetamine products within broader portfolios or do not break out individual generic products.

The addressable market is part of the broader U.S. stimulant market, which includes:

• immediate-release and extended-release amphetamine products;
• lisdexamfetamine;
• mixed amphetamine salts;
• methylphenidate products;
• branded and generic ADHD medicines;
• smaller narcolepsy demand.

Dextrostat’s addressable segment is narrower than the overall ADHD market because immediate-release dextroamphetamine is a specific clinical choice. Demand comes from patients requiring flexible dosing, rapid onset, lower-duration exposure, or a switch from other stimulant products.

The brand’s financial trajectory has therefore followed a typical mature-generic pattern:

Period	Financial trajectory
Early branded period	Higher pricing and brand-driven prescribing
Generic-entry period	Rapid price compression and volume migration
Mature generic period	Low unit economics, multiple suppliers, limited brand revenue
Supply-constrained periods	Temporary price and share volatility caused by shortages
Current strategic value	Portfolio contribution, not a standalone growth asset

Which companies compete with Dextrostat?

Competition occurs at two levels: direct pharmaceutical equivalents and therapeutic substitutes.

Direct generic competitors

The direct market includes FDA-approved generic dextroamphetamine sulfate immediate-release tablets. Supplier participation can vary by strength, manufacturing site, product availability, and shortage conditions. Major generic companies have historically participated in the broader amphetamine market, but public records should be used to confirm current applicant and marketing status for each strength. [2][4]

Branded and therapeutic competitors

Product category	Competitive effect
Dexedrine tablets	Closest branded comparator because it also contains dextroamphetamine
Generic dextroamphetamine tablets	Direct price substitute
Mixed amphetamine salts	Common clinical substitute with a different amphetamine composition
Lisdexamfetamine	Longer-acting prodrug competitor
Methylphenidate products	Alternative stimulant class
Nonstimulants	Compete where controlled-substance exposure or tolerability is a concern

Dextrostat is disadvantaged against extended-release products when prescribers prioritize once-daily dosing. It can remain relevant when clinicians want dose flexibility or a shorter duration of action.

What supply-chain factors affect Dextrostat pricing?

Controlled-substance manufacturing quotas are the main structural constraint. DEA establishes annual aggregate production quotas for Schedule I and II controlled substances, including amphetamine-related substances. Quotas are intended to balance legitimate medical demand with diversion-control requirements. [3]

Supply risk can arise from:

• insufficient quota allocation;
• active pharmaceutical ingredient constraints;
• manufacturing quality issues;
• production-line interruptions;
• shipping and wholesaler allocation limits;
• pharmacy inventory concentration;
• increased demand after shortages of competing stimulants.

The FDA Drug Shortages database has recorded shortages affecting several stimulant products and strengths. A shortage of an extended-release or mixed-amphetamine product can push demand toward immediate-release dextroamphetamine, but that substitution can also pressure the available supply of generic tablets. [4]

This creates an unusual market dynamic. Generic competition suppresses price, but limited controlled-substance capacity can produce temporary scarcity. Suppliers with dependable quota access and multiple manufacturing sites are better positioned than suppliers competing only on nominal price.

Is Dextrostat exposed to biosimilar risk?

Dextrostat has no biosimilar risk because it is a chemically synthesized small-molecule drug, not a biologic. The relevant competitive threat is generic substitution under the Abbreviated New Drug Application pathway.

The regulatory distinction is material:

Issue	Dextrostat
Biosimilar pathway	Not applicable
Generic pathway	ANDA
Interchangeability question	Pharmaceutical equivalence and state substitution rules
Main approval hurdle	Quality, bioequivalence, controlled-substance compliance, and manufacturing
Primary commercial risk	Generic price erosion and supply competition

What generic launch scenarios exist for Dextrostat?

A new generic entrant would not face a patent-based launch barrier if no enforceable listed patent blocks approval. Its main risks would be commercial and operational.

Base case

Multiple suppliers remain active. Prices stay compressed, pharmacy substitution remains high, and the brand has minimal revenue. Profitability depends on manufacturing scale, quota access, and procurement contracts.

Shortage-driven upside

A competitor experiences a manufacturing or quota disruption. Available suppliers gain temporary volume and may see improved net pricing. The effect is usually reversible because other approved suppliers can restore competition.

Persistent supply constraint

Demand rises while quota or manufacturing capacity remains fixed. Backorders become recurring, pharmacies ration inventory, and market share shifts toward firms with reliable supply. This scenario can improve revenue without creating durable brand equity.

Demand erosion

Prescribing shifts toward extended-release amphetamine, lisdexamfetamine, methylphenidate, or nonstimulant therapies. Immediate-release dextroamphetamine volume declines, limiting the value of additional manufacturing capacity.

What litigation and settlement agreements affect Dextrostat?

No major active patent litigation or Paragraph IV settlement is commercially central to the original Dextrostat brand based on its mature product profile.

Paragraph IV litigation is more relevant to newer stimulant formulations, extended-release technologies, abuse-deterrent products, or branded products with active patents. Dextrostat’s immediate-release tablet lacks the formulation complexity that typically generates a current patent litigation program.

The principal legal risks are instead:

• controlled-substance compliance;
• diversion and suspicious-order monitoring;
• FDA manufacturing enforcement;
• product liability;
• pharmacy and wholesaler contracting;
• state substitution and dispensing rules.

A generic applicant could have used a Paragraph IV certification against historical listed patents, but any such dispute would have limited present-day commercial relevance unless a patent remained enforceable. The original Dextrostat market is not dependent on a current settlement-based launch date.

How strong is the Dextrostat patent estate?

The patent estate is weak as a commercial defense.

Strength factor	Assessment
Molecular patent protection	None of current commercial value
Formulation differentiation	Limited for immediate-release tablets
Method-of-use protection	No meaningful current barrier identified
Regulatory exclusivity	Expired
Manufacturing complexity	Moderate because of controlled-substance controls
Generic substitution resistance	Low
Supply-chain defensibility	Potentially meaningful
Brand pricing power	Low

The distinction between patent strength and supply strength is important. Dextrostat has little patent leverage, but a manufacturer can still gain temporary commercial advantage through reliable supply, quota management, quality performance, and wholesaler relationships.

What is the financial outlook for Dextrostat?

The financial outlook is mature, low-growth, and supply-sensitive.

Standalone brand revenue is unlikely to be material for a large pharmaceutical company. Generic revenue can remain economically useful, but it is unlikely to produce branded-drug margins unless a supplier controls a scarce presentation during a shortage.

The most defensible revenue assumptions are:

• low or negligible branded Dextrostat growth;
• continued generic volume tied to ADHD treatment demand;
• periodic price volatility during shortages;
• limited ability to raise prices sustainably;
• greater value from supply reliability than from patent ownership;
• declining strategic value if prescribers migrate to longer-acting products.

For investors and licensing teams, Dextrostat should be valued as a mature controlled-substance generic opportunity, not as an innovative branded asset. The key diligence items are current ANDA approvals, active manufacturers by strength, FDA shortage status, DEA quota access, manufacturing-site history, and payer or wholesaler concentration.

How does Dextrostat compare with Dexedrine and extended-release stimulants?

Factor	Dextrostat	Dexedrine	Extended-release stimulants
Active ingredient	Dextroamphetamine sulfate	Dextroamphetamine-based	Varies
Duration	Immediate release	Immediate or extended release depending on product	Longer duration
Patent value	Minimal for original tablet	Depends on formulation and product	Potentially stronger for newer delivery systems
Generic pressure	High	High for older products	Varies
Dosing flexibility	High	Moderate to high	Lower
Shortage sensitivity	High	High	High
Brand pricing power	Low	Product-specific	Higher where patents or exclusivity remain

Extended-release products generally have stronger differentiation because delivery technology, release profiles, and dosing convenience can support formulation patents or historical exclusivity. Dextrostat competes primarily on clinical familiarity, immediate-release flexibility, and availability.

Key Takeaways

• Dextrostat is an older immediate-release dextroamphetamine sulfate product with no material current patent moat.
• Its original regulatory exclusivity expired long ago.
• The commercial market is dominated by generic substitution rather than branded sales.
• No biosimilar risk exists; the relevant pathway is ANDA-based generic competition.
• DEA quotas, FDA manufacturing compliance, and shortages create greater commercial barriers than patents.
• Public filings do not provide standalone Dextrostat revenue or a dependable brand-specific financial forecast.
• The product’s revenue trajectory is mature, low-margin, and vulnerable to generic price erosion.
• Temporary upside can arise during stimulant shortages, but supply-driven gains are unlikely to create durable exclusivity.
• Extended-release amphetamine and methylphenidate products are the main therapeutic competitors.
• Dextrostat has greater value as a reliable generic supply position than as a patent or licensing asset.

FAQs About Dextrostat Market Economics and Exclusivity

Is Dextrostat still commercially available?

The original branded product has a limited or discontinued commercial position, while generic dextroamphetamine sulfate tablets remain the relevant market products. Availability varies by strength, manufacturer, wholesaler inventory, and shortage conditions. [1][4]

Does Dextrostat have an active patent?

No material active patent protection for the original immediate-release Dextrostat tablet is commercially apparent. Any historical patents associated with the product would not be expected to block current generic competition.

Can a generic company launch Dextrostat without a Paragraph IV settlement?

A generic applicant can pursue approval through the ANDA pathway if no enforceable listed patent blocks approval. A Paragraph IV dispute is not inherently required for an old product with no meaningful active patent barrier.

What drives dextroamphetamine sulfate tablet prices?

Prices are driven by the number of active suppliers, manufacturing capacity, DEA quotas, FDA compliance, pharmacy purchasing contracts, and shortages affecting competing stimulant products.

Is Dextrostat a valuable licensing asset?

Its licensing value is limited as a branded asset. A transaction could have value if it includes reliable controlled-substance manufacturing capacity, quota access, approved generic products, or a differentiated delivery formulation. The original immediate-release brand alone has limited strategic value.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, Dextrostat product record. https://www.accessdata.fda.gov/scripts/cder/daf/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Drug Enforcement Administration. (2023). Established aggregate production quotas for schedule I and II controlled substances. Federal Register. https://www.federalregister.gov/

4. U.S. Food and Drug Administration. (n.d.). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/